Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/45100
Authors: 
Li, Xuan
Year of Publication: 
2008
Series/Report no.: 
Research paper / UNU-WIDER 2008.36
Abstract: 
A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug accessibility and availability (the latter is a missing parameter in the literature). Also, China lags behind in both lower R&D investment and patents filed by Chinese nationals. Based on these findings and associated legal interpretation, we conclude that higher patent protection in China generates negative impacts on the pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the anticompetitive effect in designing patent policies.
Subjects: 
product patent
process patent
TRIPS
pharmaceutical industries
China
India
JEL: 
O34
L65
F14
ISBN: 
978-92-9230-082-1
Document Type: 
Working Paper

Files in This Item:
File
Size
166.11 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.